MEI PHARMA, INC.

Analyst Reco. MEI Pharma, Inc.

Equities

MEIP

US55279B3015

Delayed Nasdaq Other stock markets 12:43:25 2024-05-08 EDT			5-day change	1st Jan Change
3.2 ^USD	+2.24%		+4.58%	-44.83%

04-11	MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	CI
04-11	MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stifel Adjusts Price Target on MEI Pharma to $7 From $8, Keeps Hold Rating	02-14	MT
Stifel Adjusts Price Target on MEI Pharma to $9 From $10, Maintains Hold Rating	23-09-27	MT
Stifel Adjusts MEI Pharma's Price Target to $10 From $0.50, Keeps Hold Rating	23-05-12	MT
Stifel Nicolaus Adjusts MEI Pharma Price Target to $0.50 From $2, Maintains Hold Rating	23-02-13	MT
HC Wainwright Adjusts Price Target on MEI Pharma to $2 From $5, Maintains Buy Rating	23-02-13	MT
Jefferies Downgrades MEI Pharma to Underperform From Hold, Adjusts Price Target to $0.10 From $0.40	23-02-08	MT
BTIG Downgrades MEI Pharma to Neutral From Buy	22-12-06	MT
Truist Securities Downgrades MEI Pharma to Hold From Buy	22-12-06	MT
Brookline Capital Markets Adjusts MEI Pharma Price Target to $15 From $20, Maintains Buy Rating	22-03-25	MT
BTIG Adjusts MEI Pharma's Price Target to $4 From $11, Reiterates Buy Rating	22-03-25	MT
Truist Securities Adjusts MEI Pharma's Price Target to $3 From $8, Reiterates Buy Rating	22-03-25	MT
Wells Fargo Downgrades MEI Pharma to Equalweight From Overweight, Adjusts Price Target to $2 From $13	22-03-25	MT
HC Wainwright Adjusts MEI Pharma's Price Target to $5 From $10, Reiterates Buy Rating	22-03-25	MT
Stifel Lowers MEI Pharma to Hold From Buy, Price Target to $2 From $6	22-03-25	MT
Jefferies Cuts MEI Pharma to Hold From Buy, Price Target to $1 From $4	22-03-25	MT
Jefferies Starts MEI Pharma at Buy With $4 Price Target	22-02-03	MT
MEI Pharma Says Treatment With Follicular Lymphoma Drug Candidate Shows Complete Response Rate of Over 35% in Mid-Stage Trial	21-11-30	MT
MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of Me-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma	17-05-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

More Top / Flop

Rankings

More Top / Flop

Currency / Forex

Commodities

Cryptocurrencies

Cryptocurrencies

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW